You are here
Bravecto® 150 mg/ml powder and solvent for suspension for injection for dogs
Bravecto injectable (Bravecto 150 mg/ml powder and solvent for suspension for injection for dogs) provides a novel long-acting approach to flea and tick control supporting convenience adding value from the year-round compliance that a single injection provides.
The product is indicated to provide immediate and persistent efficacy vs fleas and persistent efficacy versus ticks in dogs over 6 months of age. Like other Bravecto products, it contains fluralaner but its unique injectable suspension formulation allows a full 12 months duration of efficacy from a single vet-administered injection.
It is offered as a multidose vial which needs to be mixed with the supplied solvent prior to use. The single low dose of 15mg/kg (equivalent to 0.1ml per kg bodyweight) is sufficient to treat a dog for the full 12 months.The product has a 3 year shelf-life from manufacture and a 3 month shelf-life following reconstitution. Store product at room temperature (under 30oC).
Click here for more information on Bravecto Injectable.
Presentation
Powder and solvent for suspension for injection.
White to pale yellow powder and clear to opaque viscous solvent.
The reconstituted product is an opaque white to pale yellow slightly viscous suspension.
Active ingredients
Powder vial:
Active substance: Fluralaner 2.51 g
Solvent vial:
Each ml of solvent contains:
Excipient: Benzyl alcohol 22.3 mg
Reconstituted suspension:
Each ml of reconstituted suspension contains:
Active substance: Fluralaner 150 mg
Excipient: Benzyl alcohol 20.0 mg
Target species
Dogs
Indications for use
For the treatment of tick and flea infestations in dogs. This veterinary medicinal product is a systemic insecticide and acaricide that provides:
- immediate and persistent flea (Ctenocephalides felis and Ctenocephalides canis) killing activity for 12 months;
- persistent tick killing activity from 3 days to 12 months after treatment for Ixodes ricinus and Dermacentor reticulatus;
- persistent tick killing activity from 7 days to 12 months after treatment for Ixodes hexagonus;
- persistent tick killing activity from 4 days to 12 months after treatment for Rhipicephalus sanguineus.
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
For reduction of the risk of infection with Babesia canis canis via transmission by Dermacentor reticulatus from day 3 after treatment for up to 12 months. The effect is indirect due to the veterinary medicinal product’s activity against the vector.
For reduction of the risk of infection with Dipylidium caninum via transmission by Ctenocephalides felis from day 2 after treatment for up to 12 months. The effect is indirect due to the veterinary medicinal product’s activity against the vector.
Packaging
Type I glass vials closed with bromobutyl rubber stoppers and aluminium flip-off caps.
Each cardboard box contains 1, 2, 5 or 10 sets of a fluralaner powder vial (2.51 g fluralaner), a solvent vial (16 ml solvent), and a sterile 25 G vent needle.
Legal Category
POM-V
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
Product images are representations of packaging and may not accurately reflect the current packaging available in the GB marketplace.
Date of preparation: June 2024